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Introduction
Familial Mediterranean Fever (FMF) is the most common
periodic fever syndrome, characterized by recurrent fever
and serositis attacks. Colchicine is the treatment of
choice. Colchicine is given in two or three divided doses
due to its side effects. It has been stated that colchicine
unresponsive patients are in fact non-compliers because
there is an inverse relationship between daily dosage and
patient compliance.
Objectives
In this study, it was aimed to investigate whether the
once daily dosage would be as effective as twice daily
dosage regimen in reducing disease symptoms and
inflammation both in clinical and laboratory parameters
addition to manifesting with similar side effects.
Methods
Seventy-nine patients between 5 and 16 years of age
with a clinical and genetically confirmed diagnosis
of FMF and who had never received colchicine were
included in the study. The drug was started in one
or two doses randomly. A total of 42 patients received
colchicine in once daily dosage while 37 patients had in
twice daily dosage. The clinical, laboratory parameters and
drug side effects were assessed on three clinical visits two
months apart.
Results
Mean age was 7,9 ± 1,9 and 7,7 ± 2,1 years and female/
male ratio was 21/21 and 19/18 in one and two-dose
groups respectively. There were 22 patients with hetero-
zygote and 57 homozygote MEFV mutation in our study
cohort. After colchicine treatment all patients demon-
strated improvement in FMF clinical features and Mor
and Pras scores. There were no difference between one
and two-dose groups about these improvements in clini-
cal features and decreasing in Mor (p = 0,555) and Pras
(p = 0,236) scores. After colchicine treatment started the
levels of erythrocyte sedimentation rate (ESR), C reactive
protein (CRP), serum amyloid A (SAA), and S100A12
all decreased. No difference was observed between one
and two-dose groups when compared the changes in
the levels of ESR (p = 0,462), CRP (p = 0,385), SAA
(p = 0,761) and S100A12 protein (p = 0,944). Patients in
both groups manifested with side effects of colchicine
after the treatment. Although diarrhea seemed to be
more frequent among one-dose group, no significant
difference was present about side effects of the drug
between one and two-dose groups.
Conclusion
The results indicated that there was no difference between
once and twice dose groups considering improvements in
clinical and laboratory findings. Drug side effects were
similar in both groups; diarrhea was frequent in one-dose
group. Once daily dosage is as effective as twice daily
dosage scheme and can be prescribed considering the
tolerance of a patient.
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